Search
for
Sort by
Research 121–150 of 334
- GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling
- Use of Glucagon-Like Peptide-1 (GLP-1) Agonists in Modulating Preexisting Dermatologic Disease: A Systematic Review
- Risk of Alopecia Areata with Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss
- Clinical Effects of Glucagon-Like Peptide-1 Agonist Use for Weight Loss in Women With Polycystic Ovary Syndrome: A Scoping Review
- Nonscarring Alopecia in Adults Treated With GLP ‐1s: A Propensity Score Matched TriNetX Cohort Study
- Exploring the hair loss risk in glucagon‐like peptide‐1 agonists: Emerging concerns and clinical implications
- Abstract 4142154: Risk of Suicide, Hair Loss, and Aspiration with Glucagon-like Peptide 1 Receptor Agonists: A Real-World Pharmacovigilance Study from the FAERS database
- 74126 GLP-1RA Medications and Alopecia: Evaluating Risk Across Diabetic and Non-Diabetic Populations
- Hair Loss in Patients on Glucagon-Like Peptide 1 Receptor Agonists: Understanding Risks and Managing Outcomes
- Exploring the Role of GLP‐1 Agents in Managing Diabetic Foot Ulcers: A Narrative and Systematic Review
- Metabolic syndrome – a new definition and management guidelines A joint position paper by the Polish Society of Hypertension, Polish Society for the Treatment of Obesity, Polish Lipid Association, Polish Association for Study of Liver, Polish Society of Family Medicine, Polish Society of Lifestyle Medicine, Division of Prevention and Epidemiology Polish Cardiac Society, “Club 30” Polish Cardiac Society, and Division of Metabolic and Bariatric Surgery Society of Polish Surgeons
- Alopecia and Semaglutide: Connecting the Dots for Patient Safety
- Cardiovascular profile of pharmacological agents used for the management of polycystic ovary syndrome
- Maternal obesity and the metabolic syndrome in reproductive health: assessing incretin-based interventions
- CURRENT THERAPEUTIC APPROACHES IN THE MANAGEMENT OF POLYCYSTIC OVARY SYNDROME
- INDIVIDUALIZED TREATMENT OF POLYCYSTIC OVARY SYNDROME: A MANIFESTATION-GUIDED PRACTICAL APPROACH
- Telogen Effluvium and Metabolic Stress in Modern Weight Loss Interventions: A Narrative Clinical Review
- Abstracts from the 2024 WDS Forum - virtual option
- Antidiabetic Management Strategies for Treatment of Polycystic Ovarian Syndrome
- Blockbuster Weight-Loss Drugs Not Tied to Suicidality, Studies Show
- A Review of Metabolic Dysregulation in Lymphocytic Cicatricial Alopecia: Exploring the Connections and Therapeutic Implications
- Role of Sodium–Glucose Cotransporter-2 Inhibitors in Managing Polycystic Ovary Syndrome: A Systematic Review
- Methylene blue protects hair follicle stem cells from oxidative and metabolic stress to enhance hair regeneration
- Semaglutide as a Cornerstone Therapy in Obesity: Clinical and Pharmacological Insights
- Fast-tracked innovation: orforglipron approval under the FDA’s National Priority Voucher program
- Metabolic syndrome — a new definition and management guidelines
- GLP-1 e Estética: Ozempic Face, Flacidez e Recuperação
- 76708 Risk of Developing Scarring and Non-Scarring Alopecia with GLP-1 and GLP-1/GIP Agonist Utilization
- Editorial: Exploring innovative therapies for rare inflammatory skin diseases
- Treatment of insulin resistance with tirzepatide leading to improvement of hair loss